Company / Return on Equity (ROE)
Tvardi Therapeutics, Inc. Return on Equity (ROE) History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-149.7%
FY2024
5-year range
-149.7% / 3.4%
FY2020-FY2024
Trend
-285.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Tvardi Therapeutics, Inc. reports negative total equity of -149.7% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-149.7% in FY2024 with a 5-year CAGR of -82.8%.
Declined from 3.4% to -149.7% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -92.8pp
- 5-Year Change
- -82.8pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, return on equity (roe) decreased 285.2% year-over-year.
- Peak return on equity (roe) was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -149.7% | -285.2% |
| FY2023 | -38.9% | -1250.0% |
| FY2022 | 3.4% | +105.9% |
| FY2021 | -57.0% | -2.9% |
| FY2020 | -55.4% | +17.3% |
| FY2019 | -67.0% | +40.7% |
| FY2018 | -112.9% | -380.5% |
| FY2017 | -23.5% | +31.6% |
| FY2016 | -34.4% | - |
| FY2015 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026